T here is increasing evidence that inflammation plays a central role in the cascade of events that eventually results in plaque erosion and fissuring. 1 In fact, studies examining markers of inflammation demonstrate a relation between inflammation and risk of cardiovascular disease. 2 Furthermore, several studies have shown that inflammation is more common in symptomatic plaques, with greater numbers of macrophages and T cells detected in the cap of symptomatic plaques, 3 and plaque rupture has been shown to be related to increased inflammation within the plaque rather than plaque morphology or degree of vessel stenosis. 1 Macrophages synthesize proteolytic enzymes capable of degrading plaque constituents. One such family of enzymes, the matrix metalloproteinases (MMPs), is capable of degrading all macromolecular constituents of the extracellular matrix. 4 Increased expression of active MMP-2 and MMP-9 has been reported in vulnerable regions of human carotid plaques in association with macrophages. 5 Moreover, Loftus et al 6 demonstrated that MMP-9 activity is significantly higher in unstable carotid plaques. Thus, localized increase in MMP has the potential to cause the acute plaque disruption that precedes the onset of symptoms in both the coronary and cerebral circulations.
Production of MMP-2 and MMP-9 by macrophages has been shown to occur through a prostaglandin (PG) E 2 /cAMPdependent pathway. 7 Signaling through this pathway involves the modulation of cyclooxygenase (COX). 7 Two isoforms of COX have been identified, referred to as COX-1 and COX-2. 8 COX-1 is constitutively expressed and is responsible for the biosynthesis of prostaglandins involved in vascular homeostasis. In contrast, COX-2 is induced in response to growth factors, cytokines, and phorbol esters, suggesting that this enzyme is involved in the generation of prostaglandins in inflammatory diseases. Consistent with the hypothesis of COX-2 contributing to the clinical instability of coronary artery disease, incomplete suppression of thromboxane metabolite excretion has been detected in patients with unstable angina despite Ͼ95% suppression of platelet COX-1 by aspirin. 9 Moreover, the induction of COX-2 in monocytes and the resulting production of PGE 2 have been shown to be involved in MMP production by these cells. 7 Thus, the identification of pathways that may regulate MMPs is critical to the formulation of strategies that may stabilize plaques. The possibility that the simultaneous induction of COX-2 and PGE synthase (PGES) by inflammatory stimuli might represent a mechanism of plaque disruption led us to investigate whether it would modulate the production of MMP by macrophages into atherosclerotic plaques. Here, we report enhanced MMP production by macrophages in symptomatic carotid plaques, most likely due to the enhancement in PGE 2 synthesis as a result of the induction of the functionally coupled inducible COX/PGES.
Methods

Patients
We studied 50 of 66 consecutive surgical inpatients (27 male, 23 female; 72Ϯ2 years old) undergoing carotid endarterectomy for extracranial high-grade internal carotid artery stenosis (Ն70% luminal narrowing). Recruitment was completed when 2 predetermined equal groups of 25 patients according to clinical evidence of plaque instability were achieved. The first group included 25 patients who presented with symptoms of cerebral ischemic attack. Endarterectomy was performed 10 to 40 days after the onset of symptoms in these patients. The second group included 25 patients who had an asymptomatic carotid stenosis. Percentages of carotid diameter reduction, procedural methods, concomitant therapy, and risk factors did not differ between the 2 groups (Table) . By the time of surgery, all patients were taking long-term aspirin therapy (100 mg/d). The study was approved by local ethics review committees. Informed consent was obtained from all patients.
Immunohistochemistry
Serial sections were analyzed as described by Schönbeck et al. 10 Specific antibodies anti-CD68, anti-CD3, anti-HLA-DR, anti-␣-smooth muscle actin, and anti-CD31 (Dako); anti-COX-2 and anti-PGES (Cayman Chemical); and anti-MMP-2 and anti-MMP-9 (Calbiochem-Novabiochem) were used. In addition, 4 sections from each plaque were examined for the presence of plaque ulceration and intraplaque hemorrhage. The specimens were analyzed by an expert pathologist (intraobserver variability 6%) blinded to the patient's diagnosis. Quantitative Analysis was performed with a computerbased image analysis system (AlphaEase 5.02, Alpha Innotech Corp).
Reverse Transcription-Polymerase Chain Reaction
COX-2 mRNA expression was evaluated by reverse transcriptionpolymerase chain reaction (RT-PCR). RNA was reverse transcribed, and first-strand cDNA was used as a template in PCR. cDNA aliquots were amplified with primers specific for COX-2 and housekeeping gene GAPDH in a Perkin-Elmer GeneAmp 2400 cycler.
Western Blot
COX-2, PGES, MMP-2, and MMP-9 proteins were extracted and detected by Western blot as described by Jakobsson et al. 11 Bands were quantified by computer-assisted densitometry.
Zymography
Zymography was performed as described by Herron et al. 12 Conditioned medium of human fibrosarcoma cell line HT1080 was used as a positive control with known gelatinolytic activity.
Cell Isolation and Culture
Peripheral monocytes were purified and cultured as described by Fitzsimmons et al. 13 Control or stimulated (lipopolysaccharide [LPS], 1 g/mL; interleukin-1␤ [IL-1␤], 10 ng/mL) monocytes (20ϫ10 6 /4 mL of DME) were cultured in the presence or absence of the selective COX-2 inhibitor NS-398 (1 to 10 mol/L, Sigma). PGE 2 (10 Ϫ7 mol/L, Sigma) was also added to some of the cultures. The results are representative of Ն3 experiments using cells from different donors.
Statistical Analysis
Clinical and histological variables were compared by 2 test. Differences in enzyme expression and inflammatory infiltrate were analyzed by Student's t test. Statistical significance was indicated by a value of PϽ0.05. All calculations were performed with the computer program SPSS 8.0.
Results
Histological Analysis
Plaque ulceration was significantly more common in the symptomatic plaques ( (Table) .
Inflammatory Infiltration
Immunocytochemistry revealed inflammatory infiltration in all specimens examined, more evident in symptomatic plaques Intraplaque hemorrhage, n (%) 13 (52) 13 (52) Percentage of macrophage-rich areas 17Ϯ9 † 9Ϯ6
Characteristics of Study Patients
Number of T cells per mm 2 section area 65Ϯ27 † 34Ϯ19
IHD indicates ischemic heart disease; NSAID, nonsteroidal anti-inflammatory drug.
*PϽ0.05; †PϽ0.0001.
( Figure 1 ). Overall, macrophage and T-lymphocyte infiltration occurred coincidentally and was most prominent in the shoulder of the lesions and in the immediate vicinity of the atheromatous core of the lesions. Plaque area occupied by macrophages and T cells was significantly greater (PϽ0.0001) in symptomatic than in asymptomatic plaque (Table) .
Macrophage Activation in Symptomatic Plaques
The site of inflammatory infiltration in the shoulder of symptomatic plaques was always characterized by strong expression of HLA-DR antigens, which contrasted markedly with the low expression of HLA-DR in the asymptomatic plaques ( Figure 1 ). HLA-DR expression was most abundant on macrophages and lymphocytes, but HLA-DRϩ smooth muscle cells (SMCs) also occurred, although limited to sites adjacent to inflammatory infiltrates.
COX-2 Is Expressed in Macrophages of Symptomatic Plaques
Atherosclerotic lesions contained immunostainable COX-2 (Figure 2) . Interestingly, COX-2 was more abundant in symptomatic lesions, as confirmed by quantitative analysis (21.6Ϯ4.1% versus 5.6Ϯ2.6%, nϭ25, meanϮSD; PϽ0.0001). COX-2 accumulated in the shoulder region and in the periphery of the lipid core. COX-2 staining pattern indicated its localization in the activated macrophages and SMCs. Finally, the endothelium and medial SMCs of plaque vasa vasorum also showed COX-2 staining.
COX-2 Is Expressed in Higher Amounts in Symptomatic Plaques
Western blot and RT-PCR analyses revealed COX-2 expression in plaques ( Figure 3, A and B 
Regional Overexpression of PGES in Symptomatic Plaques
Immunohistochemistry revealed strong PGES immunoreactivity in all of the symptomatic plaques analyzed, but only very weak staining in the asymptomatic plaques ( Figure 2) . By quantitative image analysis, levels of PGES in symptomatic plaques significantly exceeded those in asymptomatic plaques (18.9Ϯ3.6% versus 4.1Ϯ1.6%, nϭ25, meanϮSD; PϽ0.0001), corresponding to the content of macrophages (Table) . PGES localized prominently in the shoulder region of the plaque and in the periphery of the lipid core, areas characterized as macrophage-rich.
PGES Is Expressed in Higher Amounts in Symptomatic Plaques
Only weak PGES expression was observed in asymptomatic plaques by Western blot ( Figure 3A) . In contrast, a 6-fold higher signal was demonstrated in symptomatic plaques (5482Ϯ136 versus 1028Ϯ542 DU, nϭ25, meanϮSD; PϽ0.0001).
Atherosclerotic Plaques Contain Immunoreactive MMP-2 and MMP-9
Plaques stained for both MMPs tested. Staining was significantly more abundant in the symptomatic lesions than in those of asymptomatic patients (Figure 2) . By quantitative analysis, levels (nϭ25, meanϮSD) of MMP-2 as well as MMP-9 in symptomatic plaques (23.7Ϯ5.6% and 25.2Ϯ6.1%, respectively) significantly exceeded (PϽ0.0001) those in asymptomatic plaques (8.3Ϯ2.5% and 8.8Ϯ3.3%, respectively), corresponding to the content of macrophages (Table) . Immunoreactivity localized especially in the shoul- der and the fibrous cap of the lesions, corresponding to areas of intense macrophage infiltration.
Symptomatic Plaques Contain Activated MMPs
The increased (PϽ0.0001) MMP-2 and MMP-9 immunoreactivity documented in symptomatic plaques by Western blot (5746Ϯ263 versus 2522Ϯ321 and 5980Ϯ722 versus 3562Ϯ981 DU, respectively; nϭ25, meanϮSD) ( Figure 4 ) does not necessarily correspond to augmented enzymatic activity, because all MMPs require activation before they can digest their substrate. 14 Thus, we used zymography to demonstrate that extracts from symptomatic plaques contained the activated form of MMP-2 ( Figure 4 ) and MMP-9. In contrast, only weak positivity for activated MMPs was observed in asymptomatic plaques. Thus, the amount (nϭ25, meanϮSD) of inactive and active MMP-2 (4622Ϯ322 versus 1244Ϯ932 and 2522Ϯ348 versus 822Ϯ391 DU, respectively) and MMP-9 (4136Ϯ829 versus 2136Ϯ788 and 2788Ϯ1036 versus 1181Ϯ961 DU, respectively) was significantly higher (PϽ0.0001) in the symptomatic plaques.
Colocalization of COX-2, PGES, and MMPs in Macrophages in Symptomatic Plaques
In the first experiment, serial sections of symptomatic plaques were incubated with the primary antibodies anti-CD68, anti-COX-2, anti-PGES, anti-MMP-2, and anti-MMP-9 ( Figure  5 ). Within the lesion, all enzymes accumulated in the shoulder as well as in the periphery of the lipid core. In the second experiment, immunofluorescence double-labeling associated the expression of PGES with COX-2 and MMPs in CD68ϩ macrophages ( Figure 6 ). Thus, these analyses confirmed the concomitant presence of COX-2, PGES, and MMPs in macrophages at the vulnerable region of symptomatic plaque.
PGE 2 -Dependent Production of MMPs in Monocytes In Vitro
To determine whether monocyte MMP production is regulated through a PGE 2 -dependent pathway involving the concomitant induction of functionally coupled COX-2 and PGES, we initially examined the effect of NS-398 on MMP production ( Figure 7 ). LPS caused a strong enhancement in COX-2, PGES, MMP-2 and MMP-9 levels over those detected in control monocytes. COX-2 and MMP induction by LPS was significantly inhibited by NS-398; the inhibition of MMPs was reversed, however, by the addition of PGE 2 . Similar results were also observed when interleukin-1␤ was used as stimulus. Thus, MMP production appears to be secondary to the induction of functionally coupled COX-2 and PGES and the subsequent generation of PGE 2 .
Discussion
In the present report, we provide evidence for the functionally coupled involvement of COX-2 and PGES in MMP overexpression in symptomatic human atherosclerotic plaques. In particular, the present findings are the first, to the best of our knowledge, to (1) identify evidence for PGES in human atherosclerotic lesions and (2) relate the pattern of the inducible COX/PGES pathway to an acute ischemic event often precipitated by rupture of atherosclerotic plaque. Concomitantly higher expression of COX-2, PGES, MMP-2, and MMP-9 was found in specimens obtained from the "culprit" carotid lesions of patients with recent transient ischemic attack (TIA) or stroke compared with specimens obtained from asymptomatic patients. In fact, only 4 of 25 (16%) of the asymptomatic plaques exhibited an intensity of enzyme expression comparable to those observed in symptomatic plaques, whereas the remaining specimens demonstrated only weak positivity.
There are several possible explanations for why Ϸ16% of asymptomatic plaques showed an enzyme expression comparable to those observed in plaques from patients with recent TIA or stroke. Postmortem studies 15 suggest that plaque rupture is sometimes asymptomatic. Thus, silent plaque rupture resulting in nonocclusive thrombosis can occur in patients who do not develop the clinical hallmarks of any of the syndromes associated with plaque rupture. Accordingly, 2 of 4 asymptomatic patients in this study who nevertheless demonstrated high expression for COX-2, PGES, and MMPs have been in this category. Alternatively, the other patients, had they not undergone atherectomy, might have soon progressed to frank plaque rupture and one of the cerebral ischemic events.
In this study, macrophages were significantly more abundant in complicated plaques, always outnumbered the lymphocytes, and represented the major source of COX-2/PGES, MMP-2, and MMP-9. The site of inflammatory infiltration was always characterized by strong expression of HLA-DR antigens on inflammatory cells, which contrasted markedly with the low expression of HLA-DR elsewhere in the fibrous cap. Thus, these data suggest the presence of an active inflammatory reaction in symptomatic plaques. In fact, in agreement with the difference in COX-2/PGES and MMP staining pattern, the histological milieu of the lesions appears to be different with regard to cellularity, presence of foam cells, and cholesterol clefts but not in the degree of vessel stenosis, suggesting that asymptomatic and symptomatic lesions are different only with regard to inflammatory burden and that differences in plaque behavior stem from differences in the presence of as yet undetermined stimuli for specific expression of Ն1 proteins capable of disrupting plaque stability.
Previous studies 10, 16, 17 have reported COX-2 expression in atherosclerotic lesions. These studies, however, did not provide any evidence about the real involvement of COX-2 in the pathophysiology of atherosclerotic plaque rupture. In fact, COX-2 is only an intermediate enzyme in the metabolic pathway of arachidonic acid, and the COX by-product PGH 2 is further metabolized by other isomerases to various prostanoids (PGE 2 , PGD 2 , PGF 2␣ , PGI 2 , thromboxane A 2 ). Thus, the relative abundance of one specific prostanoid rather than another is the result of the expression and activity of its specific isomerase, and only the concomitant expression of functionally coupled COX-2 and PGES may lead to increased biosynthesis of PGE 2 -dependent MMPs in the setting of atherosclerotic plaque.
Interestingly, macrophages of the shoulder region contain most of the COX-2 protein within the lesion. This finding may have functional importance, because different cell types can regulate the production of different eicosanoids. Endothelium releases predominantly PGI 2 , 18 an inhibitor of platelet activation and cholesterol accumulation, 18 and Belton et al 16 recently reported that COX-2 is responsible for the increase in PGI 2 seen in patients with atherosclerosis. In contrast, macrophages, not present in normal arterial tissue, produce an array of prostanoids, including PGE 2 , 19 considered one of the most atherogenic eicosanoids. The finding that COX-2 localizes predominantly with lesional macrophages agrees with observations in abdominal aortic aneurysms, in which macrophages also represent the majority of COX-expressing cells. 20 Increased COX-2 expression within the plaque further agrees with reports describing COX-2 expression in atheroma-associated cells, including macrophages, on stimulation with proinflammatory cytokines such as IL-1, tumor necrosis factor-␣, and CD40L, mediators found within human atherosclerotic lesions. 21 Recently, the intriguing and novel proatherogenic mechanism of the functionally coupled inducible COX/PGES has been supported by the demonstration that membrane-bound PGES expression is markedly induced by proinflammatory stimuli in various tissues and cells and is downregulated by dexamethasone, accompanied by changes in COX-2 expression and delayed PGE 2 generation. 22 Moreover, Jakobsson et al 11 showed that COX-2 and PGES are coregulated in nucleated cells by inflammatory stimuli and that PGE 2 biosynthesis may depend on the presence of both of these enzymes. In accordance with this, an inducible PGES activity has been described in LPS-stimulated rat peritoneal macrophages, which coincides with COX-2 expression and changes the product formation in favor of PGE 2 . 23 Our study thus agrees with published data demonstrating a severalfold increase in PGE 2 biosynthesis and COX-2 protein in A549 cells in response to IL-1␤ 24 and is the first to suggest that overexpression of the functionally coupled COX-2/PGES may realize a predominant pathway of arachidonate metabolism leading to increased biosynthesis of PGE 2 -dependent MMPs in the setting of human atherosclerotic plaque.
Prostanoids have potent actions on vascular SMCs, regulating contractility, cholesterol metabolism, and proliferation. 25 Increased expression of COX might thus contribute to the accumulation of lipids in lesional SMCs (and macrophages), favoring formation of SMC-and macrophage-de- rived foam cells within atheroma. Conversely, antiproliferative and antimigratory 26 actions of COX products on SMCs suggest potential contributions of the enzymes to the evolution of a lesion toward an SMC-depleted and macrophageenriched, and thus more vulnerable, plaque. Furthermore, COX-2 can modulate angiogenesis by synthesis of angiogenic factors and neovessel formation. Consequently, COX-2 expression within the lesion contributes to the formation of new blood vessels, thus allowing the plaque to expand. 27 More importantly, PGE 2 , a predominant eicosanoid of macrophages, induces the expression of MMP-2 and MMP-9, enzymes considered crucial in the degradation of plaque stability. 7 Our description of these metalloproteinases in plaque regions that are COX-2/PGES-positive and found to be macrophage-enriched suggests that such regulation of MMP expression by COX products may operate in vivo. Furthermore, we found that asymptomatic plaques expressed substantially less COX-2/PGES and MMP than symptomatic lesions. Our results are in agreement with those of Loftus et al, 6 demonstrating higher MMP-9 activity in unstable plaques. In contrast, because no previous works have established an association between MMP-2 and vulnerable plaques, further studies will be necessary to define the precise role of MMP-2 in the setting of plaque instability.
In conclusion, this study addresses the missing link between COX-2 overexpression and plaque instability by demonstrating the high prevalence of the functionally coupled COX-2/PGES in human atherosclerotic lesions and providing evidence that synthesis of the inducible COX/PGES by activated macrophages is associated with TIA and stroke, possibly by MMP-induced matrix degradation promoting plaque rupture. These findings are potentially important from a fundamental standpoint, because they indicate a pathogenetic role for the inducible COX/PGES in the evolution of atherosclerotic lesions. From a practical standpoint, these findings raise the possibility that the selective COX-2 inhibitors now currently available for clinical use or future PGES inhibitors might provide a novel form of therapy for plaque stabilization of patients with atherosclerotic disease and prevention of acute ischemic syndromes. . PGE 2 -dependent MMP production in monocytes. Purified monocytes were cultured in presence or absence of NS-398 at indicated concentrations for 30 minutes, and then LPS and PGE 2 were added to some cultures. Cultures were harvested at 48 hours for Western blot analysis.
